Form 4: Blueprint Medicines Officer Reports Share Transactions Following Sanofi Merger Completion

Ariel Hurley, Principal Accounting Officer of Blueprint Medicines Corp, reported the disposition of common stock and stock options, and acquisition of shares from performance units, all in connection with the company's merger with Sanofi, effective July 17, 2025.

Summary

• Blueprint Medicines Corp (BPMC) completed its merger with Sanofi, where Rothko Merger Sub, Inc., a wholly-owned subsidiary of Aventis Inc. (itself a wholly-owned subsidiary of Sanofi), merged with and into Blueprint Medicines Corp.
• The merger became effective on July 17, 2025, with Blueprint Medicines Corp surviving as an indirect wholly-owned subsidiary of Sanofi.
• Under the merger agreement, a tender offer was completed to acquire all outstanding common stock of Blueprint Medicines Corp for $129.00 per share in cash, plus one contractual contingent value right (CVR) per share.
• Ariel Hurley, Principal Accounting Officer, reported the acquisition of 2,460 shares of common stock, which were previously performance-based stock units (PSUs) that were deemed earned based on the greater of target and actual performance at the effective time.
• Hurley disposed of 16,146 shares of common stock, which were tendered in exchange for the Offer Consideration.
• An additional 3,378 shares of common stock were disposed of, representing restricted stock units (RSUs) that were cancelled and converted into the right to receive the Offer Consideration.
• All outstanding stock options held by Hurley, whether vested or unvested, became fully vested and were cancelled, converting into the right to receive the Cash Offer Price less the exercise price, plus one CVR for each share underlying the option.
• A total of 66,976 stock options with various exercise prices ranging from $36.05 to $100.13 were disposed of.
• Following these transactions, Ariel Hurley beneficially owns 0 shares of common stock and 0 derivative securities of Blueprint Medicines Corp.

Sentiment

Score: 8

Explanation: The sentiment is highly positive as the filing confirms the successful completion of a merger at a premium, providing liquidity and a defined value for shareholders, and full vesting of equity awards for the reporting person, with potential for additional value from CVRs.

Positives

• The merger completion provides liquidity and a defined value for Blueprint Medicines Corp shareholders.
• All outstanding performance-based stock units (PSUs) and stock options held by the reporting person became fully vested at the effective time of the merger.
• The inclusion of a Contingent Value Right (CVR) offers potential for additional future payments based on the achievement of certain milestones.

Negatives

• Blueprint Medicines Corp ceased to be an independent, publicly traded company, becoming an indirect wholly-owned subsidiary of Sanofi.
• The reporting person no longer holds any common stock or derivative securities of Blueprint Medicines Corp.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on the achievement of specific future milestones, which may or may not occur.
• Fifty percent of PSUs, RSUs, and stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, introducing a future vesting condition for a portion of the compensation.

Future Outlook

The future outlook for former Blueprint Medicines Corp shareholders includes potential contingent payments from the CVRs upon the achievement of specified milestones. Blueprint Medicines Corp will operate as an indirect wholly-owned subsidiary of Sanofi.

Management Comments

• Securities were transacted pursuant to the Agreement and Plan of Merger by and among Blueprint Medicines Corp, SANOFI, Aventis Inc., and Rothko Merger Sub, Inc.
• Purchaser completed a tender offer to acquire all issued and outstanding shares of common stock for $129.00 per share plus one contractual contingent value right per share.
• At the effective time of the merger, each performance-based stock unit (PSU) was deemed earned based on the greater of target and actual performance and converted into the right to receive the Offer Consideration, with 50% of 2025 PSUs converting into cash-based awards subject to continued vesting.
• At the effective time, each outstanding restricted stock unit (RSU) was cancelled and automatically converted into the right to receive the Offer Consideration, with 50% of 2025 RSUs converting into cash-based awards subject to continued vesting.
• At the effective time, each share of common stock held by the reporting person was tendered in exchange for the Offer Consideration.
• At the effective time, each outstanding stock option became fully vested, was cancelled, and converted into the right to receive the Cash Offer Price less the applicable exercise price, plus one CVR, with 50% of 2025 options converting into cash-based awards subject to continued vesting.

Industry Context

This transaction represents a significant acquisition in the biotechnology and pharmaceutical sector, where larger pharmaceutical companies like Sanofi acquire specialized biotech firms such as Blueprint Medicines Corp to expand their pipeline, particularly in precision oncology. Such mergers are common strategies for growth and diversification in the industry.

Comparison to Industry Standards

• The tender offer and subsequent merger structure is a standard approach for corporate acquisitions in the pharmaceutical and biotechnology industries.
• The use of Contingent Value Rights (CVRs) is a common mechanism in biotech acquisitions to bridge valuation gaps and share future development risks and rewards, particularly for assets in clinical development or awaiting regulatory milestones. While no specific comparable companies or projects are mentioned in the document, this CVR structure aligns with industry practices for such deals.

Stakeholder Impact

• Shareholders received the agreed-upon cash consideration and CVRs for their shares, providing a clear exit and potential future upside.
• Employees, including the reporting person, had their equity awards converted or vested according to the merger terms, ensuring compensation for their contributions.
• Blueprint Medicines Corp as an entity ceased independent public operations, becoming part of a larger corporate structure under Sanofi.

Next Steps

• Achievement of milestones that would trigger contingent payments under the CVRs.
• Integration of Blueprint Medicines Corp's operations and assets into Sanofi's broader portfolio.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Performance Stock Units, CVR, Contingent Value Right, Corporate Action